Search results for "esophageal neoplasms"

showing 10 items of 136 documents

Surgical anatomy of the upper esophagus related to robot-assisted cervical esophagectomy

2021

Abstract Robot-assisted cervical esophagectomy (RACE) enables radical surgery for tumors of the middle and upper esophagus, avoiding a transthoracic approach. However, the cervical access, narrow working space, and complex topographic anatomy make this procedure particularly demanding. Our study offers a stepwise description of appropriate dissection planes and anatomical landmarks to facilitate RACE. Macroscopic dissections were performed on formaldehyde-fixed body donors (three females, three males), according to the surgical steps during RACE. The topographic anatomy and surgically relevant structures related to the cervical access route to the esophagus were described and illustrated, a…

Aortic archMaleEsophageal Neoplasmsmedicine.medical_treatmentThoracic ductEsophagusRobotic Surgical Proceduresmedicine.arterymedicineHumansEsophagusbusiness.industryGastroenterologySympathetic trunkCarotid sheathGeneral MedicineFasciaAnatomyThoraxEsophagectomyTracheaDissectionmedicine.anatomical_structureEsophagectomyFemalebusinessDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
researchProduct

Confocal laser endoscopy: new approach to the early diagnosis of tumors of the esophagus and stomach

2006

The prognosis of malignancies of the upper gastrointestinal tract is poor if early diagnosis is missed. Therefore, a rapid in vivo diagnosis of early cancer and premalignant lesions is highly important for succesful therapy. Confocal laser endomicroscopy allows in vivo cellular and subcellular imaging at high resolutions during ongoing endoscopy. The first studies and clinical observations suggest a major role of this novel technique in the in vivo diagnosis of cancer of the esophagus and stomach and of precursor conditions, such as Barrett’s esophagus, intestinal metaplasia of the stomach and Helicobacter pylori infection. Based on recent experiences from animal models, future studies wil…

Cancer ResearchPathologymedicine.medical_specialtyEsophageal NeoplasmsEndoscopy GastrointestinalStomach NeoplasmsmedicineHumansEsophagusMicroscopy Confocalbiologymedicine.diagnostic_testbusiness.industryStomachCancerIntestinal metaplasiaGeneral MedicineHelicobacter pyloriEsophageal cancermedicine.diseasebiology.organism_classificationEndoscopymedicine.anatomical_structureOncologyBarrett's esophagusbusinessFuture Oncology
researchProduct

Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.

2008

This study aimed to define the co-expression pattern of target receptor tyrosine kinases (RTKs) in human esophageal adenocarcinoma and squamous cell cancer. The co-expression pattern of vascular endothelial growth factor receptor (VEGFR)1-3, platelet-derived growth factor receptor (PDGFR)alpha/beta and epidermal growth factor receptor 1 (EGFR1) was analyzed by RT-PCR in 50 human esophageal cancers (35 adenocarcinomas and 15 squamous cell cancers). In addition, IHC staining was applied for the confirmation of the expression and analysis of RTK localisation. The adenocarcinoma samples revealed VEGFR1 (97%), VEGFR2 (94%), VEGFR3 (77%), PDGFRalpha (91%), PDGFRbeta (85%) and EGFR1 (97%) expressi…

Cancer ResearchPathologymedicine.medical_specialtyReceptor Platelet-Derived Growth Factor alphaEsophageal NeoplasmsAdenocarcinomaReceptor tyrosine kinaseReceptor Platelet-Derived Growth Factor betaGrowth factor receptormedicineHumansEpidermal growth factor receptorVascular Endothelial Growth Factor Receptor-1biologyOncogeneCancerReceptor Protein-Tyrosine KinasesGeneral Medicinemedicine.diseaseVascular Endothelial Growth Factor Receptor-3ImmunohistochemistryVascular Endothelial Growth Factor Receptor-2ErbB ReceptorsOncologyEpidermoid carcinomacardiovascular systembiology.proteinCancer researchCarcinoma Squamous CellAdenocarcinomaPlatelet-derived growth factor receptorOncology reports
researchProduct

Analysis of Antiproliferative and Chemosensitizing Effects of Sunitinib on Human Esophagogastric Cancer Cells: Synergistic Interaction With Vandetani…

2009

The receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 1-3 (VEGFR1-3), are frequently expressed in gastric cancer and are putative therapeutic targets in this disease. We have investigated the anti-proliferative and chemosensitizing properties of the multitargeted small-molecule RTK inhibitors sunitinib and vandetanib in a panel of 4 human gastric and esophageal cancer cell lines. In the 1st instance, the expression of potential targets of these small-molecule inhibitors was examined by reverse transcriptase-polymerase chain reaction, western blotting, and flow cytometry. EGFR mRNA and protein was detected in all cases, …

Cancer ResearchUmbilical VeinsIndolesEsophageal NeoplasmsApoptosisVandetanibTyrosine-kinase inhibitorReceptor tyrosine kinasechemistry.chemical_compoundPiperidinesSunitinibMedicineDrug InteractionsEpidermal growth factor receptorPhosphorylationCells CulturedbiologySunitinibReverse Transcriptase Polymerase Chain ReactionDrug SynergismFlow CytometryErbB ReceptorsOncologyPhosphorylationDrug Therapy Combinationmedicine.drugSignal Transductionmedicine.medical_specialtymedicine.drug_classBlotting WesternAntineoplastic AgentsStomach NeoplasmsInternal medicineHumansPyrrolesPropidium iodideRNA MessengerProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-1business.industryCancermedicine.diseaseVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2EndocrinologychemistryCancer researchbiology.proteinQuinazolinesEndothelium VascularbusinessProto-Oncogene Proteins c-akt
researchProduct

The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease

2009

Recently, a Global definition and a classification of gastroesophageal reflux disease (GERD) were developed by Montreal Consensus Group, composed of international expert gastroenterologists. Guidelines and consensus documents are, however, infrequently accepted and adopted at a local level. The aim of this study was to measure the acceptance of Montreal Global definition of GERD consensus document by specialists in a single country (Italy) and to measure the linguistic, scientific, and practical differences between the international consensus document and the Italian version.A 2-day meeting was held in June 2007 in Rome, Italy, attended by 147 Italian physicians who were experts in gastroen…

Chest Painmedicine.medical_specialtyValidation studyEsophageal NeoplasmseducationMEDLINEDiseaseAdenocarcinomaGastroenterologyBarrett EsophagusTerminology as TopicInternal medicineHumansMedicineLanguageEvidence-Based MedicineHepatologybusiness.industryGastroenterologyRefluxSyndromeEvidence-based medicinemedicine.diseasedigestive system diseasesItalyEsophageal stenosisFamily medicinePractice Guidelines as TopicEsophageal StenosisGastroesophageal RefluxGERDbusinessPremalignant lesionEuropean Journal of Gastroenterology & Hepatology
researchProduct

The molecular changes driving the carcinogenesis in Barrett's esophagus: which came first, the chicken or the egg?

2013

Esophageal adenocarcinoma originates from columnar metaplastic epithelium of the distal esophagus. Various steps for this carcinogenetic process are known. Before the onset of high-grade dysplasia and adenocarcinoma, endoscopic surveillance is possible. However, because of the high cost of long-term surveillance, predictive factors for cancer are being evaluated to identify subjects with metaplasia who have a higher risk of developing malignancy. Molecular changes seem suitable for this purpose, but could require a high resource expenditure. While trying to identify the best predictive factors for cancer risk, molecular changes and differences in miRNA expression profile between the various…

DysplasiaPathologymedicine.medical_specialtyEsophageal NeoplasmsSettore MED/06 - Oncologia MedicaCarcinogenesisSettore MED/08 - Anatomia PatologicaAdenocarcinomaMalignancymedicine.disease_causeBarrett EsophagusMetaplasiamicroRNAmedicineHumansMetaplasiabusiness.industryEndoscopic surveillanceCancerBarrett's esophaguBarrett's esophagus; Metaplasia; Dysplasia; Adenocarcinoma; Endoscopic surveillance; miRNAsHematologymedicine.diseaseSettore MED/18 - Chirurgia GeneraleMicroRNAsOncologyDysplasiaBarrett's esophagusmiRNAsCancer researchDisease ProgressionAdenocarcinomamedicine.symptombusinessCarcinogenesisBiomarkersCritical reviews in oncology/hematology
researchProduct

Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia.

2007

Background and study aims Endoscopic resection of esophageal squamous-cell neoplasia with curative intent is considered to be a safe and effective alternative treatment to radical surgery in cases where the neoplasia is intraepithelial or limited to the mucosal layer. These patients are at risk for recurrent malignancy in the preserved esophagus, however. We conducted a prospective study to evaluate the efficacy and safety of endoscopic resection and to analyze variables associated with recurrence in patients with mucosal or intraepithelial squamous-cell neoplasia. Patients and methods Between December 1997 and September 2005, 65 patients (mean age +/- standard deviation [SD] 62.9 +/- 9.5 y…

Endoscopic ultrasoundMalemedicine.medical_specialtyEsophageal NeoplasmsmedicineCarcinomaHumansProspective StudiesEsophagusRadical surgerySurvival rateAgedNeoplasm StagingIntraepithelial neoplasiamedicine.diagnostic_testEsophageal diseasebusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureHigh Grade Intraepithelial NeoplasiaFemaleEsophagoscopybusinessCarcinoma in SituEndoscopy
researchProduct

Internet-based perioperative exercise program in patients with Barrett’s carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomize…

2017

Abstract Background Patients undergoing surgery for esophageal cancer have a high risk for postoperative deterioration of lung function and pulmonary complications. This is partly due to one-lung ventilation during thoracotomy. This often accounts for prolonged stay on intensive care units, delayed postoperative reconvalescence and reduced quality of life. Socioeconomic disadvantages can result from these problems. Physical preconditioning has become a crucial leverage to optimize fitness and lung function in patients scheduled for esophagectomy, in particular during the time period of neoadjuvant therapy. Methods/Study design We designed a prospective multicenter randomized-controlled tria…

InternetTime FactorsEsophageal NeoplasmsOesophageal cancer610 MedizinInternet-basedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Perioperative CareExercise TherapyRespiratory Function TestsEsophagectomyTranslational Research BiomedicalStudy ProtocolTreatment Outcome610 Medical sciencesHumansPerioperativeProspective StudiesExerciseBMC Cancer
researchProduct

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

2021

Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. Here, we describe the design and rationale for the double-blind, Phase III, placebo-co…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyClinical Trial ProtocolEsophageal Neoplasmsesophageal adenocarcinomamedicine.medical_treatmentPembrolizumabAntibodies Monoclonal Humanizedchemotherapy03 medical and health sciences0302 clinical medicineClinical ProtocolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansesophageal cancerradiotherapyChemotherapybusiness.industryCancerChemoradiotherapyGeneral MedicineEsophageal cancermedicine.diseaseCombined Modality Therapyesophageal squamous cell carcinomaRadiation therapyClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemaleimmunotherapypembrolizumabbusinessChemoradiotherapyFuture Oncology
researchProduct